Clinical Trial Update: A Study to Assess TTI-0102 vs Placebo in MELAS Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating TTI-0102 versus placebo in MELAS patients is currently recruiting. The sponsor is Thiogenesis Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melas Syndrome
• Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like Episodes

Drugs mentioned

• TTI-0102

Snippet

Sponsor: Thiogenesis Therapeutics, Inc. | Conditions: MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS) | Phase 2 | Status: RECRUITING